Efficacy and safety of anlotinib-based treatment in metastatic breast cancer patients

HIGHLIGHTS

• who: Yu Qian and colleagues from the at Buffalo, United States have published the research work: Efficacy and safety of anlotinib-based treatment in metastatic breast cancer patients, in the Journal: (JOURNAL)
• what: Among them, grade 3-4 bone marrow suppression represented by neutropenia and thrombocytopenia are often the main reasons leading to dose reduction or drug withdrawal.
• how: The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). Since the study was a single-arm retrospective study with no control group the authors investigated the previous single . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.